{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:40:36Z","timestamp":1762864836630},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.euroneuro.2004.05.008","type":"journal-article","created":{"date-parts":[[2004,12,2]],"date-time":"2004-12-02T00:24:20Z","timestamp":1101947060000},"page":"103-110","source":"Crossref","is-referenced-by-count":19,"title":["Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo\u2013possible involvement of different mechanisms"],"prefix":"10.1016","volume":"15","author":[{"given":"W.A.","family":"Daniel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Haduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"W\u00f3jcikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2004.05.008_BIB1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-5728(99)00176-9","article-title":"Dopamine, a neurotransmitter, influences the immune system","volume":"102","author":"Basu","year":"2000","journal-title":"J. Neuroimmunol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0006-8993(97)00428-9","article-title":"Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones","volume":"765","author":"Baum","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/00498259509061859","article-title":"Metabolism of thioridazine by microsomal monooxygenases: relative roles of P-450 and flavin-containing monooxygenase","volume":"25","author":"Blake","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.1983.40","article-title":"Desipramine hydroxylation: effect of antipsychotic drugs","volume":"33","author":"Bock","year":"1983","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB5","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/0006-2952(86)90493-4","article-title":"Bufuralol 1\u2032-hydroxylase activity of the rat","volume":"35","author":"Boobis","year":"1986","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3109\/00498259009046835","article-title":"Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors","volume":"20","author":"Boobis","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/mcp.2002.127494","article-title":"The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment","volume":"72","author":"Brockmoller","year":"2002","journal-title":"Clin. Pharamacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00614194","article-title":"Steady-state levels of imipramine and ist metabolites: significance of dose-dependent kinetics","volume":"30","author":"Br\u00f8sen","year":"1986","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB9","first-page":"188","article-title":"Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver","volume":"27","author":"Chow","year":"1999","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB10","first-page":"685","article-title":"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P-450 2D6, 1A2 and 3A4\u2014implications for susceptibility to Parkinson's disease","volume":"227","author":"Coleman","year":"1996","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00008571-199304000-00001","article-title":"Genetically variable metabolism of antidepressant and neuroleptic drugs","volume":"3","author":"Dahl","year":"1993","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","article-title":"Disposition of perphenazine is related to the polymorphic hydroxylation in human beings","volume":"46","author":"Dahl-Puustinen","year":"1989","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB13","first-page":"197","article-title":"Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats","volume":"43","author":"Daniel","year":"1991","journal-title":"Pol. J. Pharmacol. Pharm"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB14","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/0006-2952(86)90420-X","article-title":"The effect of neuroleptics on imipramine demethylation in rat liver microsomes and imipramine and desipramine level in the rat brain","volume":"35","author":"Daniel","year":"1986","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":"Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants","volume":"131","author":"Daniel","year":"2000","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1211\/0022357001777685","article-title":"Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats","volume":"52","author":"Daniel","year":"2000","journal-title":"J. Pharm. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1211\/002235702162","article-title":"Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants","volume":"54","author":"Daniel","year":"2002","journal-title":"J. Pharm. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0924-977X(02)00053-6","article-title":"The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics","volume":"12","author":"Daniel","year":"2002","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0009-2797(84)90084-X","article-title":"Irreversible binding of the chlorpromazine radical cation and of photoactivated chlorpromazine to biological macromolecules","volume":"52","author":"de Mol","year":"1984","journal-title":"Chem. Biol. Interact"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0009-2797(86)90050-5","article-title":"Irreversible binding with biological macromolecules and effect of bacterial mutagenity tests on the radical cation of promethazine and photoactivated promethazine. Comparison with chlorpromazine","volume":"57","author":"de Mol","year":"1986","journal-title":"Chem. Biol. Interact"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00007691-200106000-00008","article-title":"Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test","volume":"23","author":"Eap","year":"2001","journal-title":"Ther. Drug Monit"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041444-200010010-00002","article-title":"Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (aims) score","volume":"10","author":"Ellingrod","year":"2000","journal-title":"Psychiatr. Genet"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1023\/A:1006938908284","article-title":"Metabolism, pharmacogenetics, and metabolic drug\u2013drug interactions of antipsychotic drugs","volume":"19","author":"Fang","year":"1999","journal-title":"Cell. Mol. Neurobiol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB24","first-page":"1638","article-title":"In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes","volume":"12","author":"Fang","year":"2001","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1520\/JFS10149J","article-title":"Phenothiazines: metabolism and analytical detection","volume":"17","author":"Forrest","year":"1972","journal-title":"J. Forens. Sci"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/004982597240802","article-title":"Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybrydization","volume":"27","author":"Gilham","year":"1997","journal-title":"Xenobiotica"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00007691-199105000-00007","article-title":"A simple, rapid method for the simultenaous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection","volume":"13","author":"Glare","year":"1991","journal-title":"Ther. Drug Monit"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/331442a0","article-title":"Characterization of the common genetic defect in humans deficient in debrisoquine metabolism","volume":"331","author":"Gonzalez","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0773.1974.tb00742.x","article-title":"Pharmacokinetic interaction between neuroleptics and tricyclic antidepressants in the rat","volume":"35","author":"Gram","year":"1974","journal-title":"Acta Pharmacol. Toxicol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB30","doi-asserted-by":"crossref","first-page":"863-44-55","DOI":"10.1176\/ajp.131.8.863","article-title":"Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man","volume":"131","author":"Gram","year":"1974","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB31","first-page":"83","article-title":"Mycloperoxidase-generated phenothiazine cation radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase","volume":"34","author":"Gutierrez-Correa","year":"2002","journal-title":"Rev. Argent. Microbiol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB32","first-page":"36","article-title":"Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals","volume":"33","author":"Gutierrez-Correa","year":"2001","journal-title":"Rev. Argent. Microbiol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/10715760100300311","article-title":"Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals","volume":"34","author":"Gutierrez-Correa","year":"2001","journal-title":"Free Radic. Res"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0773.1994.tb00357.x","article-title":"Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat","volume":"75","author":"Hals","year":"1994","journal-title":"Pharmacol. Toxicol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","article-title":"Dopamine formation from tyramine by CYP2D6 biochem","volume":"249","author":"Hiroi","year":"1998","journal-title":"Biophys. Res. Commun"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB36","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1210\/en.142.9.3901","article-title":"Progesterone oxidation by cytochrome P450 2D isoforms in the brain","volume":"142","author":"Hiroi","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1124\/dmd.30.9.970","article-title":"Catalytic specificity of CYP2D isoforms in rat and human","volume":"30","author":"Hiroi","year":"2002","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(96)90111-3","article-title":"The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol","volume":"59","author":"Jerling","year":"1996","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0003-9861(91)90301-X","article-title":"Oxidation of chlorpromazine by methemoglobin in the presence of hydrogen peroxide. Formation of chlorpromazine radical cation and its covalent binding to methemoglobin","volume":"284","author":"Kelder","year":"1991","journal-title":"Arch. Biochem. Biophys"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB41","first-page":"889","article-title":"The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene","volume":"45","author":"Kimura","year":"1989","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB42","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/0006-2952(89)90433-4","article-title":"The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man","volume":"38","author":"Kobayashi","year":"1989","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB43","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/0024-3205(95)00223-S","article-title":"Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism","volume":"56","author":"Kroemer","year":"1995","journal-title":"Life Sci"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB44","first-page":"247","article-title":"A sensitive fluorometric assay for morphine in plasma and brain","volume":"145","author":"Kupfenberg","year":"1964","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB45","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/0006-2952(92)90485-2","article-title":"Effects of interleukin 1\u03b1 on the activities and gene expressions of the cytochrome P450IID subfamily","volume":"44","author":"Kurokohchi","year":"1992","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/clpt.1993.197","article-title":"Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents","volume":"54","author":"Llerna","year":"1996","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00007691-200008000-00006","article-title":"Use of the mesoridazine\/thioridazine ratio as a marker for CYP2D6 enzyme activity","volume":"22","author":"Llerna","year":"2000","journal-title":"Ther. Drug Monit"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007691-200112000-00004","article-title":"Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes","volume":"23","author":"Llerna","year":"2001","journal-title":"Ther. Drug Monit"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB49","first-page":"431","article-title":"The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan","volume":"30","author":"Maj","year":"1978","journal-title":"Pol. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02099942","article-title":"The rat debrisoquine 4-hydroxylase CYP2D gene subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme binding region of the cytochrome P450 active site","volume":"30","author":"Matsunaga","year":"1990","journal-title":"J. Mol. Evol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00316110","article-title":"Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type","volume":"39","author":"Meyer","year":"1990","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB52","first-page":"1232","article-title":"Physiological and pathophysiological regulation of cytochrome P450","volume":"26","author":"Morgan","year":"1998","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s002280050079","article-title":"Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolizers of debrisoquine","volume":"50","author":"Muralidharan","year":"1996","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB54","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/ajp.137.10.1232","article-title":"Neuroleptic effect on desipramine steady-state plasma concentration","volume":"137","author":"Nelson","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB55","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0024-3205(90)90128-E","article-title":"Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ), a possible parkinsonian inducing substance, in an animal model of a poor debrisoquine metabolizer","volume":"46","author":"Ohta","year":"1990","journal-title":"Life Sci"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0304-4165(96)00046-3","article-title":"Differential effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat","volume":"1291","author":"Rane","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB57","first-page":"62","article-title":"Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism","volume":"26","author":"Reggiani","year":"2000","journal-title":"Encephale"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00008571-199906000-00011","article-title":"Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression","volume":"9","author":"Schulz-Utermoehl","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14622416.3.2.201","article-title":"Cytochrome P450 polymorphisms and response to antipsychotic therapy","volume":"3","author":"Scordo","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB60","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s002280000222","article-title":"CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients","volume":"56","author":"Scordo","year":"2000","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB61","first-page":"1078","article-title":"Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6","volume":"27","author":"Shin","year":"1999","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2125.2001.01313.x","article-title":"Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol","volume":"51","author":"Shin","year":"2001","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/clpt.1988.76","article-title":"Inhibition of desipramine 2-hydroxylation by quinidine and quinine","volume":"43","author":"Steiner","year":"1988","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB64","first-page":"89","article-title":"Inhibitory effects of neuroleptics on debrisoquine oxidation in man","volume":"22","author":"Syv\u00e4lahti","year":"1986","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB65","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-0773.1999.tb02018.x","article-title":"A comparison of the effect of five phenothiazines on hepatic CYP isoenzymes in rats","volume":"85","author":"Tateishi","year":"1999","journal-title":"Pharmacol. Toxicol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB66","first-page":"1120","article-title":"Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid","volume":"294","author":"Thompson","year":"2000","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0006-291X(92)91777-N","article-title":"Regulation of cytochrome P450 IID by acute phase mediators in C3H\/HeJ mice","volume":"182","author":"Trautwein","year":"1992","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB68","first-page":"924","article-title":"Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan","volume":"27","author":"Tyndale","year":"1999","journal-title":"Drug Metab. Dispos"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00433047","article-title":"Interaction between amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response","volume":"65","author":"Vandel","year":"1979","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB70","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s002280050689","article-title":"Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes","volume":"55","author":"Vandel","year":"1999","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB71","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/abbi.1997.0402","article-title":"Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity","volume":"348","author":"Wan","year":"1997","journal-title":"Arch. Biochem. Biophys"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-2952(88)90756-3","article-title":"Interactions of hepatic cytochromes P-450 with steroid hormones","volume":"37","author":"Waxman","year":"1988","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002280050278","article-title":"Parmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function","volume":"52","author":"Wong","year":"1997","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB74","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0006-2952(94)00481-Z","article-title":"Ethylmorphine O-deethylation in isolated rat hepatocytes","volume":"49","author":"Xu","year":"1995","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199802000-00010","article-title":"Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2","volume":"8","author":"Yamamoto","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(00)00613-5","article-title":"Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes","volume":"67","author":"Yoshii","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.euroneuro.2004.05.008_BIB77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008571-200303000-00007","article-title":"Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6","volume":"13","author":"You","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X04000902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X04000902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T18:24:17Z","timestamp":1549045457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X04000902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0924977X04000902"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2004.05.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}